Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States

Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015;163(3):215-223.

Publication Type:

Journal Article

Authors:

Barua, S.; Greenwald, R.; Grebely, J.; Dore, G.J.; Swan, T.; Taylor, L.E.

Source:

Ann Intern Med, Volume 163, Issue 3, p.215-223 (2015)

Keywords:

alcohol, Antiretroviral, Antiretroviral Therapy, co-infected, co-infection, coinfection, Consensus, coverage, Disease, District of Columbia, Fibrosis, Food, HCV, hepatitis, Hepatitis C, hepatitis C virus, Hiv, HIV RNA, Infection, Liver, Liver Diseases, Medicaid, Organizations, Rna, Societies, sofosbuvir, therapy, treatment, United States, urine

Cited On:

Overview of Cost, Reimbursement, and Cost-Effectiveness Considerations for Hepatitis C Treatment Regimens

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/26120969

Export Citation:

RIS Format

Top